Multiomics Market Size, Share, Growth, and Industry Analysis, By Type (Single-cell Multiomics,Bulk Multiomics), By Application (Cell Biology,Oncology,Neurology,Immunology,Others), Regional Insights and Forecast to 2035

Multiomics Market Overview

The global Multiomics Market size is projected to grow from USD 3563.41 million in 2026 to USD 3983.89 million in 2027, reaching USD 9669.53 million by 2035, expanding at a CAGR of 11.8% during the forecast period.

The global multiomics market integrates genomics, transcriptomics, proteomics, metabolomics, and other omics layers, supporting more than 3,000 concurrent studies worldwide in 2024 and over 250,000 samples processed annually using multiomics pipelines. Demand for multiomics workflows surged by 42 % in the decade 2014–2024 across pharmaceutical, academic, and agricultural sectors.

The United States leads multiomics adoption: in 2024, U.S. institutions conducted over 1,200 multiomics projects, representing about 45 % of global project volume. U.S. labs processed an estimated 90,000 multiomics samples in 2024, across more than 400 academic and biopharma centers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 38 % of multiomics demand in 2024 derives from oncology and biomarker discovery applications
• Major Market Restraint: 25 % of respondents cite data integration complexity as major barrier to adoption
• Emerging Trends: 32 % of multiomics vendors now bundle AI/ML analytics within platform offerings
• Regional Leadership: North America represented approximately 47 % share of the global multiomics market in 2024
• Competitive Landscape: Top 5 multiomics companies captured around 22 % of the instrument and software market in 2024
• Market Segmentation: Bulk multiomics accounted for 60 % share of sample volume in 2024
• Recent Development: In 2023–2025, 15 new multiomics integration tools launched globally

Multiomics Market Latest Trends

In recent years, the multiomics market has shifted toward highly integrated workflows, combining genomics, transcriptomics, proteomics, and metabolomics in unified pipelines. In 2024, more than 320 new multiomics workflows were published publicly, reflecting growth of system biology research. Instrument vendors are increasingly offering hybrid solutions: in 2024, 28 % of new instrument launches included multi-omics compatibility rather than single-omics only.

Multiomics Market Dynamics

The Multiomics Market Dynamics section provides an in-depth understanding of how technological, scientific, and strategic factors collectively shape the global multiomics landscape. In 2024, more than 500 active vendors offered integrated multiomics platforms, processing over 250,000 samples annually across academic, clinical, and industrial laboratories. Key Multiomics Market Drivers include the exponential rise in precision medicine programs—where approximately 40 % of oncology clinical trials now incorporate multiomics endpoints—and the expansion of national genomic initiatives across 25 countries supporting systems-level research..

DRIVER

"Increasing demand for precision medicine and biomarker-driven development"

In the field of precision medicine, multiomics provides richer and more actionable biomarker signatures. Over 40 % of oncology clinical trials initiated in 2023 incorporated multiomics endpoints versus single-omics alone. Pharmaceutical companies allocated over USD 850 million toward multiomics discovery in 2024. Multiomics integration enables stratification of patient subpopulations in immuno-oncology trials—30 % higher resolution of responders was reported in trials using multiomics profiling. Academic consortia such as large cohort studies now sequence multiomics layers across 25,000 participants in population research.

RESTRAINT

"Data integration complexity and lack of standardization"

One key restraint is the complexity of combining diverse omics data modalities. Around 25 % of users report integration failures or inconsistencies across transcriptomics and proteomics data. Another 18 % cite interoperability issues across vendor platforms. Without standard ontologies and data schemas, pipelines differ: over 50 distinct multiomics software pipelines exist globally, causing reproducibility problems. In 2024, 16 % of multiomics projects were delayed due to data harmonization and normalization issues.

OPPORTUNITY

"Expansion of single-cell and spatial multiomics in clinical diagnostics"

Single-cell and spatial multiomics are opening new frontiers. In 2024, more than 170 new spatial multiomics studies were published across oncology, neurology, and developmental biology. Clinical research in immuno-oncology leveraged spatial multiomics to identify tumor microenvironment cell neighborhoods in over 2,500 patient samples. New clinical diagnostics companies now bundle multiomics panels: in 2023, 5 startups launched combined multiomics kits intended for disease stratification.

CHALLENGE

"High costs of instrumentation, reagent consumables, and scalable infrastructure"

Though sequencing costs have declined, proteomics and metabolomics remain expensive. In 2024, per sample multiomics cost averaged USD 1,500–2,000, which restricts usage in lower-budget labs. Capital expenditures for integrated omics instruments range from USD 0.8–1.5 million each, placing entry beyond many institutions. Reagent and consumables costs account for 35–45 % of overall project cost. The need for more advanced compute infrastructure—often 500 TB+ storage and GPU clusters—exceeds many institutions’ capacity.

Multiomics Market Segmentation

The Multiomics Market Segmentation is divided by Type and Application to reveal adoption patterns and addressable niches. In Multiomics Market Research Report, segmentation by type—Single-cell Multiomics and Bulk Multiomics—and by application—Cell Biology, Oncology, Neurology, Immunology, Others—allows firms to tailor offerings. Volume share, usage contexts, and technology demands differ strongly between types and applications in the Multiomics Market Analysis.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Single-cell Multiomics: Single-cell multiomics focuses on profiling individual cells across multiple molecular layers (e.g. transcriptome + epigenome + proteome). It accounted for about 40 % of commercial project volume in 2024, growing faster in R&D labs. Over 220 publications in 2024 used single-cell multiomics in immunology and cancer studies. Laboratories running single-cell multiomics typically process 1,000 to 10,000 cells per run, with throughput increasing by 30 % year-on-year. The technology is preferred in developmental, immuno-oncology, and neural lineage studies for resolving cellular heterogeneity. Its adoption is constrained by instrumentation cost, but more integrated single-cell multiomics kits appeared in 2023–2025, reducing setup complexity by 25 %.
• Bulk Multiomics: Bulk multiomics aggregates molecular signals from tissue or population-level samples, representing about 60 % of sample throughput in 2024. Bulk multiomics is widely used in biomarker discovery, toxicogenomics, and agricultural trait profiling. In 2024, bulk multiomics assays processed over 500,000 samples globally. Bulk protocols are more mature, with typical assays spanning ~5 to 10 omics layers and standard pipelines. Many CROs still rely on bulk multiomics due to cost efficiency: about 70 % of multiomics service contracts in 2024 used bulk methods. Bulk multiomics remains preferred in population-scale studies, clinical cohorts (e.g. 10,000+ patients), and agricultural screening programs covering thousands of genotypes.

BY APPLICATION

• Cell Biology: In cell biology applications, multiomics is used to characterize differentiation, signaling pathways, and cellular states. Around 18 % of multiomics projects in 2024 were in cell biology. Studies typically integrate transcriptomics + proteomics + epigenomics across cell lines, primary cells, or organoids. Researchers processed ~45,000 samples in 2024 under the cell biology domain. Multiomics Market Research Reports show many labs now adopt standard protocols with 6 omics modalities per sample. Cell biology remains a foundational domain enabling systems-level exploration before translation to disease fields.
• Oncology: Oncology is the largest single application by project count: in 2024, 37 % of multiomics studies focused on cancer (solid tumors, hematologic malignancies). Over 150 multiomics-based biomarker discovery pipelines were active in pharmaceutical pipelines in 2024. Cancer consortia allocated ~USD 420 million toward multiomics integration. Multiomics in oncology often integrates genomics, transcriptomics, proteomics, and metabolomics across 10,000+ tumor samples in large cohorts. Multiomics Market Trends show that cancer projects now frequently use 5–7 omics layers per sample to elucidate tumor microenvironment and resistance pathways.
• Neurology: Neurology applications represent ~12 % of multiomics projects in 2024. Projects examining Alzheimer’s, Parkinson’s, and neurodegeneration frequently pair transcriptomics, metabolomics, and proteomics across brain tissue, CSF, and blood. In 2024, neurological multiomics initiatives processed ~8,000 samples across cohort studies. Multiomics Market Insights indicate increasing efforts to integrate spatial multiomics in brain slices: ~20 pilot spatial workflows launched in 2024. Neurology projects often require delicate sample prep, and some labs combine single-cell multiomics with spatial proteomics across 50,000+ cells.
• Immunology: Immunology accounted for about 16 % of multiomics studies in 2024. Multiomics in immunology integrates transcriptome, epigenome, proteome, and metabolome from sorted immune cells, often from 20,000–100,000 cell sets. Immunology-driven multiomics enables characterization of immune states in cancer, vaccination, and autoimmunity. More than 90 immuno-multiomics protocols were published in 2023–2024. Companies offering immunology-focused multiomics kits and pipelines grew by 30 % in 2024. Immunology applications are central to multiomics adoption in therapeutic development and patient stratification.
• Others: “Others” includes applications in agriculture, environmental science, microbiome, and metabolic disease, making up ~17 % of multiomics projects in 2024. In agriculture, ~25 crop improvement programs in 2024 used multiomics for genotype–phenotype correlation. Environmental microbiome multiomics spanned ~15,000 microbial samples globally. Multiomics in metabolic disease settings processed ~12,000 patient samples focusing on metabolomic + proteomic integration. This category continues growing as multiomics expands beyond human health into broader life sciences domains.

Regional Outlook for the Multiomics Market

The Multiomics Market Regional Outlook section examines performance and adoption trends across North America, Europe, Asia-Pacific, and the Middle East & Africa, offering quantitative insights into geographical leadership and market distribution. In 2024, North America held approximately 47 % global market share, supported by over 1,200 ongoing research projects, 150 core facilities, and significant federal funding for multiomics programs. Europe accounted for about 20 %–22 % share, processing over 60,000 samples annually across major countries including Germany, the United Kingdom, and France.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the global multiomics market, accounting for roughly 47 % share of multiomics project volume and instrument/software adoption in 2024. The United States remains the powerhouse: U.S. institutions executed over 1,200 multiomics research projects, processed 90,000 samples, and consumed nearly 48 % of global multiomics software licenses. Canada also contributes meaningfully via its national genomics center and translational research grants. Core facilities in North America (over 150 major centers) handle the highest throughput multiomics workflows.

The North America Multiomics Market is estimated to reach a market size of USD 1,398.2 million in 2025, holding a 43.9% global share, and projected to grow steadily at a CAGR of 11.6% through 2034, supported by robust research infrastructure, strong government funding, and a large concentration of biotechnology and pharmaceutical companies integrating genomics, proteomics, and metabolomics data into precision medicine workflows across the region.

North America – Major Dominant Countries in the Multiomics Market

• United States: Holds a market size of USD 950.6 million in 2025, capturing 68% regional share and expected to grow at a CAGR of 11.8%, driven by high adoption in clinical genomics, oncology trials, and single-cell multiomics platforms across more than 1,200 research facilities.
• Canada: Estimated at USD 204.7 million in 2025, representing 14.6% regional share and projected to grow at a CAGR of 11.5%, supported by national genomics programs, translational medicine initiatives, and expansion of academic multiomics laboratories in Toronto and Vancouver.
• Mexico: Accounts for USD 87.9 million in 2025, securing 6.3% share and growing at a CAGR of 11.7%, driven by government partnerships with biotech firms and the establishment of multiomics data centers for infectious disease research and agricultural bioscience.
• Panama: Estimated at USD 41.5 million in 2025, representing 3% regional share and expanding at a CAGR of 11.3%, supported by clinical biomarker discovery projects, university-led omics laboratories, and international collaborations in precision healthcare.
• Cuba: Holds a market value of USD 30.4 million in 2025, capturing 2.1% share and projected to grow at a CAGR of 11.1%, boosted by public investment in bioinformatics and metabolomics research within national biotechnology institutes.

EUROPE

Europe represents a significant multiomics hub, capturing around 20 %–22 % share of global multiomics activity in 2024. Major contributors include Germany, United Kingdom, France, Netherlands, and the Nordic countries, which host key academic consortia, biotech firms, and national disease initiatives. European multiomics projects processed over 60,000 samples in 2024, spanning cancer, neurology, immunology, and translational disease programs. The European Union has funded multiomics consortium grants exceeding EUR 300 million in the 2021–2024 funding cycle. Many pan-European research programs mandate multiomics layers in disease cohorts, contributing to a strong baseline of adoption. European regulators and harmonization bodies foster cross-border data sharing, enabling multiomics datasets to flow among member states.

The Europe Multiomics Market is expected to reach a market size of USD 863.6 million in 2025, accounting for 27.1% global share and projected to expand at a CAGR of 11.7% through 2034, fueled by strong governmental research grants, cross-border collaboration projects, and growing demand for personalized medicine solutions across oncology, neurology, and immunology sectors within leading European countries.

Europe – Major Dominant Countries in the Multiomics Market

• Germany: Holds a market size of USD 224.5 million in 2025, representing 26% share of the European market and expected to grow at a CAGR of 11.9%, driven by high investments in proteogenomics, multiomics AI platforms, and pharmaceutical innovation hubs across Berlin and Munich.
• United Kingdom: Estimated at USD 186.7 million in 2025, securing 21.6% share and projected to grow at a CAGR of 11.6%, supported by advanced omics infrastructure, government-backed genomics programs, and strong collaborations between NHS trusts and biopharma companies.
• France: Records a market size of USD 149.2 million in 2025, accounting for 17.3% regional share and forecasted to grow at a CAGR of 11.5%, driven by oncology-based multiomics studies, government innovation funding, and clinical implementation of integrated omics diagnostics.
• Netherlands: Holds USD 103.6 million in 2025, representing 12% market share and growing at a CAGR of 11.8%, supported by its bioinformatics ecosystem, academic multiomics centers, and focus on metabolomics-based population health research.
• Italy: Estimated at USD 76.8 million in 2025, capturing 8.9% share and projected to grow at a CAGR of 11.4%, propelled by adoption of bulk and single-cell multiomics for neurological and cardiovascular disease modeling within national research institutions.

ASIA-PACIFIC

Asia-Pacific is among the fastest-growing regions for multiomics, holding approximately 25 %–27 % share and rising adoption across China, Japan, India, South Korea, and Australia. In 2024, Asia-Pacific multiomics labs processed over 80,000 samples, with China alone contributing ~35,000 runs. Chinese government initiatives invested USD 400 million+ toward precision health and multiomics integration between 2022 and 2024. India launched national multiomics projects in 2023 across over 20 medical centers, processing ~5,000 samples in the first year. Japanese and South Korean biotech firms adopted multiomics pipelines across oncology, neurology, and microbiome domains. Regional consortia in Asia coordinate multiomics data across multiple institutions, overcoming infrastructure gaps.

The Asia Multiomics Market is forecasted to reach a market size of USD 734.8 million in 2025, representing a 23% global share and anticipated to expand at a CAGR of 12.1% through 2034, driven by government-funded genomics initiatives, rapid biopharmaceutical development, and expanding research networks across China, Japan, India, South Korea, and Singapore supporting integrated multiomics data platforms for clinical and agricultural applications.

Asia – Major Dominant Countries in the Multiomics Market

• China: Holds a market size of USD 273.2 million in 2025, capturing 37.2% regional share and growing at a CAGR of 12.3%, driven by national investments in omics-based drug discovery, large-scale sequencing centers, and emerging biotech startups specializing in AI-powered multiomics analysis.
• Japan: Estimated at USD 162.9 million in 2025, representing 22.2% share and projected to grow at a CAGR of 12.0%, fueled by academic-industry partnerships, healthcare digitalization, and the integration of proteomics and metabolomics platforms within advanced research institutes.
• India: Records a market size of USD 121.5 million in 2025, accounting for 16.5% regional share and expected to expand at a CAGR of 12.4%, supported by the establishment of national genome centers, medical genomics startups, and growing public-private investments in life sciences.
• South Korea: Holds a market value of USD 97.4 million in 2025, securing 13.3% regional share and forecasted to grow at a CAGR of 12.2%, driven by pharmaceutical multiomics adoption, AI integration for clinical trial analytics, and government R&D incentives.
• Singapore: Estimated at USD 79.8 million in 2025, capturing 10.8% share and projected to grow at a CAGR of 12.1%, supported by its advanced biotechnology ecosystem, translational medicine programs, and regional leadership in omics data standardization and integration.

MIDDLE EAST & AFRICA

The Middle East & Africa region currently accounts for approximately 6 % share of global multiomics activity, but shows growing momentum in translational research, agriculture, and public health initiatives. In 2024, MEA multiomics facilities processed ~10,000 samples, mainly in South Africa, UAE, Saudi Arabia, and Egypt. The UAE and Saudi Arabia launched national precision medicine programs incorporating multiomics panels at 5 major academic hospitals. In South Africa, multiomics consortia supported over 1,200 cancer and infectious disease samples in cross­-African studies. Egypt and North African research centers piloted multiomics workflows in neurological and metabolic disease cohorts (~1,500 samples).

The Middle East and Africa Multiomics Market is expected to reach a market size of USD 190.7 million in 2025, representing 6% of the global total and projected to grow at a CAGR of 11.4% through 2034, driven by rising investment in healthcare genomics, precision medicine initiatives, and expansion of research infrastructure across Gulf nations and African biotechnology hubs.

Middle East and Africa – Major Dominant Countries in the Multiomics Market

• United Arab Emirates: Holds a market size of USD 54.2 million in 2025, representing 28.4% regional share and expected to grow at a CAGR of 11.6%, supported by national precision medicine strategies, genomic research funding, and partnerships with global omics technology firms.
• Saudi Arabia: Estimated at USD 45.7 million in 2025, capturing 24% share and projected to grow at a CAGR of 11.5%, driven by healthcare modernization programs, national data-driven disease research, and investments in omics laboratories within major universities.
• South Africa: Holds USD 38.1 million in 2025, representing 20% share and expected to expand at a CAGR of 11.3%, fueled by genomic diversity projects, agricultural multiomics studies, and the establishment of multiomics core facilities for regional academic use.
• Egypt: Records a market value of USD 29.3 million in 2025, accounting for 15.3% share and projected to grow at a CAGR of 11.2%, driven by growing public health genomics initiatives, bioinformatics capacity building, and infectious disease multiomics studies.
• Qatar: Estimated at USD 23.4 million in 2025, securing 12.3% share and expected to grow at a CAGR of 11.4%, supported by translational medicine research, international multiomics collaborations, and investments in metabolic and proteogenomic diagnostics.

List of Top Multiomics Companies

• BD
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Danaher (Beckman Coulter)
• PerkinElmer, Inc.
• Shimadzu Corporation
• Bruker
• QIAGEN
• Agilent Technologies, Inc.
• BGI Genomics

Illumina, Inc.: Illumina, Inc. leads the multiomics market with advanced sequencing and genomic integration technologies, holding around 13% share, supporting over 1,000 global research projects and large-scale precision medicine programs.

Thermo Fisher Scientific, Inc.: Thermo Fisher Scientific, Inc. dominates multiomics instrumentation and analytics solutions, capturing about 11% share, providing integrated platforms for proteomics, metabolomics, and transcriptomics across pharmaceutical, clinical, and academic research sectors worldwide.

Investment Analysis and Opportunities

Investments in the multiomics sector are accelerating: between 2022 and 2024, venture deals targeting multiomics startups totaled over USD 450 million, spanning instrument, analytics, and sample processing firms. Private equity and institutional capital are entering multiomics platforms supporting clinical trials, spatial omics, and AI-driven interpretation, with roughly 25 funding rounds to date. Infrastructure investments in compute and storage systems tied to multiomics projects exceeded USD 200 million globally in 2023. Regional governments and R&D agencies in Asia and Europe committed USD 150–200 million in multiomics facility grants in 2023–2024.

Investment opportunities exist in multiomics software pipelines, AI/ML integrative platforms, reagent kits optimized for multiplexed assays, and microfluidic sample prep systems. Multiomics Market Opportunities also arise in establishing contract multiomics service labs in emerging regions—12 new multiomics CROs were launched in Asia in 2024. Investors may seed spatial omics firms, single-cell multiomics startups, and federated analysis/data sharing models. Joint ventures between instrumentation firms and academic centers are appearing: 8 such consortia initiated between 2023–2025. Capital infusion into reagent consumables, scalable automation, and secure cloud infrastructure for multiomics processing is expected to yield attractive returns as adoption continues to expand.

New Product Development

Innovation in the multiomics market is marked by integrated multi-layer assay kits, modular sample prep systems, and AI-native analytics stacks. In 2023, two leading companies released multiplexed omics kits that reduce sample input requirement by 30 % while combining transcriptome + proteome + metabolome in one workflow. In 2024, spatial multiomics systems capable of imaging up to 10 omics modalities were launched by three vendors, enabling high-definition molecular maps. In late 2024, microfluidic single-cell multiomics systems that profile 5 modalities in 1,000 cells per run were introduced. Some new products embed on-chip barcoding and library prep to reduce hands-on time by 40 %. In 2025, a hybrid instrument integrating mass spectrometry and sequencing modules enables proteogenomic analyses within 24 hours per sample.

Several multiomics analytics platforms released AI-powered modules able to interpret multi-layer data across 10,000 genes, 500 proteins, and 200 metabolites in one pass. New cloud platforms offer federated access to >1 petabyte of multiomics datasets, with built-in security and compliance. A notable product debut in 2025 is a spatial transcriptometabolomics instrument that images metabolites and gene expression in the same tissue section. Another innovation is reagent kits that stabilize nucleic acids, proteins, and metabolites simultaneously, reducing cold chain burden by 25 %. These advances in assay kits, instrumentation, and AI pipelines are central to Multiomics Market Research Report and Multiomics Market Insights narratives.

Five Recent Developments

• In 2023, a leading multiomics company launched a reagent kit combining transcriptome + proteome + metabolome profiling from single samples, reducing assay turnaround time by 25 %.
• In 2024, three vendors released spatial multiomics systems enabling 10 omics modalities per tissue section, expanding multiplexing capabilities and spatial resolution.
• In late 2024, a new instrument integrating sequencing and mass spectrometry modules was introduced, able to complete proteogenomic workflows within 24 hours per sample.
• In 2025, a microfluidic single-cell multiomics platform was launched that profiles 5 omics layers across 1,000 cells per run, reducing hands-on sample prep time by 40 %.
• In 2025, a cloud multiomics analytics platform released federated access to >1 petabyte of multiomics datasets with built-in encryption, compliance, and real-time multiomics interpretation pipelines.

Report Coverage of Multiomics Market

The Multiomics Market Research Report covers historical data from 2015–2024, baseline metrics for 2024–2025, and projections through 2030 (or beyond). It includes unit shipments, sample throughput volumes, assay layer adoption trends, and technological maturity curves across platforms and workflows. The report provides 200+ charts and tables detailing multiomics project counts, instrument adoption rates, reagent kit volumes, analytics software licensing, and regional deployment summaries. The scope includes Multiomics Market Report, Multiomics Market Analysis, Multiomics Industry Report, Multiomics Market Forecast, Multiomics Market Trends, Multiomics Market Share, Multiomics Market Insights, and Multiomics Market Opportunities.

Multiomics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3563.41 Million in 2026
Market Size Value By	USD 9669.53 Million by 2035
Growth Rate	CAGR of 11.8% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Single-cell Multiomics Bulk Multiomics By Application : Cell Biology Oncology Neurology Immunology Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample